Selective Activation of the Adrenomedullin Receptors in Migraine

NCT ID
NCT07451769
Registry status
Recruiting
Study type
Interventional
Phase
Not applicable
Sponsor
Danish Headache Center
Conditions
Adrenomedullin, Brain Diseases, Central Nervous System Diseases, Migraine, Neuropeptides, Pain, Peptides, Signs and Symptoms

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

Enrollment: 26 participants (Estimated).

What is being studied

  • Drug: Adrenomedullin
  • Intervention: Adrenomedullin
  • Intervention: Amino Acids, Peptides, and Proteins
  • Intervention: Hormones
  • Intervention: Hormones, Hormone Substitutes, and Hormone Antagonists
  • Intervention: Peptide Hormones
  • Intervention: Peptides
  • Other: Placebo

Who may be eligible

Ages
18 Years to 65 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: 1. Written informed consent has been obtained prior to the initiation of any study-specific procedures. 2. Age ≥18 years at the time of screening. 3. History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and/or patient self-report, and diagnosed in accordance with the ICHD-3 criteria. Exclusion Criteria: 1. History of any other primary headache disorder, except for tension-type headache with \<5 headache days per month, based on ICHD-3 classification. 2. History of any secondary headache disorder, per ICHD-3 criteria, prior to screening. 3. Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening. 4. Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists. 5. Known risk of self-harm or harm to others, including a history of suicidal behavior. 6. Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity. 7. Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential. 8. Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period. 9. Evidence of current pregnancy or breastfeeding based on self-report or medical records. 10. Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.

Study locations

1 study location is listed.

Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.

Countries: Denmark

Sample of listed locations

  • Danish Headache Center — Glostrup Municipality, 2600, Denmark — Recruiting

Study details

Start date
March 12, 2026
Primary completion date
March 10, 2027
Completion date
December 20, 2032
First posted
March 5, 2026

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07451769
Registry last updated
August 28, 2026
QualifiedStudies registry data refreshed
October 5, 2026
QualifiedStudies record fetched
October 5, 2026

View NCT07451769 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Migraines studies | Clinical trial FAQ